ESMO-IO 2019 – Personalised ovarian cancer vaccines show promise


  • Carolina Rojido
  • Univadis
L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano

Takeaway

  • Personalised vaccines from neoantigens using dendritic cells as targets for activation could radically improve overall survival.1

Why this matters

  • Most patients with ovarian cancer (85%) relapse after first-line treatment.
  • Intratumoral T cells have been found to be present in 55% of ovarian tumours.

Key results

  • Very few grade 3-4 adverse events.
  • Clinical response correlated with immune response (IFN).
  • T-cell responses induced by the vaccine were polyfunctional.
  • Conclusions on personalised whole tumour antigen vaccines:
    • Induce responses that correlate with progression-free survival.
    • 2-year overall survival (OS) rates of the responder patients were 100%, whereas the 2-year OS of non-responders were 25%.2
    • Must be combined with standard of care immunomodulatory treatment (bevacizumab and cyclophosphamide) for added synergistic effect.
    • Enhanced pre-existing response against some neo-epitopes and induced newly detected responses against additional neo-epitopes.
    • Have potential in patients with low mutational load for which a sufficient amount of tumour is available to produce the vaccine.

Study design

  • Phase 1 clinical trial of autologous dendritic cell vaccine loaded with autologous tumour cell lysate for recurring ovarian cancer.
  • The immunogenicity of tumour cells was optimised by exposing them to hypochlorous acid.
  • Administration was by intra-nodal injection.
  • Average 16 doses per patient and 174 intranodal injections.

Limitations

  • Very small, early stage study.